Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer.

Cheng J, Moore S, Gomez-Galeno J, Lee DH, Okolotowicz KJ, Cashman JR.

J Pharmacol Exp Ther. 2019 Dec;371(3):703-712. doi: 10.1124/jpet.119.261040. Epub 2019 Oct 3.

PMID:
31582422
2.

Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53.

Cheng J, Okolotowicz KJ, Ryan D, Mose E, Lowy AM, Cashman JR.

Am J Cancer Res. 2019 Feb 1;9(2):390-405. eCollection 2019.

3.

Novel tertiary sulfonamides as potent anti-cancer agents.

Okolotowicz KJ, Dwyer M, Ryan D, Cheng J, Cashman EA, Moore S, Mercola M, Cashman JR.

Bioorg Med Chem. 2018 Aug 15;26(15):4441-4451. doi: 10.1016/j.bmc.2018.07.042. Epub 2018 Jul 25.

PMID:
30075999
4.

A Novel Inhibitor Targets Both Wnt Signaling and ATM/p53 in Colorectal Cancer.

Cheng J, Dwyer M, Okolotowicz KJ, Mercola M, Cashman JR.

Cancer Res. 2018 Sep 1;78(17):5072-5083. doi: 10.1158/0008-5472.CAN-17-2642. Epub 2018 Jul 21.

5.

1,5-Disubstituted benzimidazoles that direct cardiomyocyte differentiation from mouse embryonic stem cells.

Okolotowicz KJ, Bushway P, Lanier M, Gilley C, Mercola M, Cashman JR.

Bioorg Med Chem. 2015 Sep 1;23(17):5282-92. doi: 10.1016/j.bmc.2015.07.073. Epub 2015 Aug 4.

6.

Preclinical studies of noncharged oxime reactivators for organophosphate exposure.

Okolotowicz KJ, Dwyer M, Smith E, Cashman JR.

J Biochem Mol Toxicol. 2014 Jan;28(1):23-31. doi: 10.1002/jbt.21519. Epub 2013 Aug 13.

PMID:
23943350
7.

Inhibition of Bfl-1 with N-aryl maleimides.

Cashman JR, MacDonald M, Ghirmai S, Okolotowicz KJ, Sergienko E, Brown B, Garcia X, Zhai D, Dahl R, Reed JC.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6560-4. doi: 10.1016/j.bmcl.2010.09.046. Epub 2010 Sep 21.

8.

Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules.

Peddibhotla S, Shi R, Khan P, Smith LH, Mangravita-Novo A, Vicchiarelli M, Su Y, Okolotowicz KJ, Cashman JR, Reed JC, Roth GP.

J Med Chem. 2010 Jun 24;53(12):4793-7. doi: 10.1021/jm1000248.

9.

Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway.

Okolotowicz KJ, Shi R, Zheng X, MacDonald M, Reed JC, Cashman JR.

Bioorg Med Chem. 2010 Mar 1;18(5):1918-24. doi: 10.1016/j.bmc.2010.01.039. Epub 2010 Jan 25. Erratum in: Bioorg Med Chem. 2011 Feb 1;19(3):1367.

PMID:
20153655
10.

Chemical biology strategy reveals pathway-selective inhibitor of NF-kappaB activation induced by protein kinase C.

Shi R, Re D, Dudl E, Cuddy M, Okolotowicz KJ, Dahl R, Su Y, Hurder A, Kitada S, Peddibhotla S, Roth GP, Smith LH, Kipps TJ, Cosford N, Cashman J, Reed JC.

ACS Chem Biol. 2010 Mar 19;5(3):287-99. doi: 10.1021/cb9003089.

11.

Inactivation of protein farnesyltransferase by active-site-targeted dicarbonyl compounds.

Okolotowicz KJ, Lee WJ, Hartman RF, Kim AY, Ottersberg SR, Robinson DE Jr, Lefler SR, Rose SD.

Arch Pharm (Weinheim). 2001 Jun;334(6):194-202.

PMID:
11475909

Supplemental Content

Loading ...
Support Center